A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Trial Profile

A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs ASP 8062 (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 May 2018.
    • 21 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 May 2018.
    • 17 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top